| Experience with recombinant factor VIIa in Australia and New Zealand. | |
| | |
MedLine Citation:
|
PMID: 8904184 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Recombinant factor VIIa (rFVIIa; NovoSeventrademark) was availablefor compassionate use in Australia and New Zealand from 1991 to 1994. Over this period there were 18 treatment episodes in 9 patients, age 8-66 years, with haemophilia A and high titre inhibitors cross-reacting with porcine factor VIII. There were no significant adverse effects. Treatment with rFVIIa resulted in a successful outcome in 8 potentially life-threatening (retroperitoneal, subdural, gastro-intestinal) bleeds. Elective cystoscopy, repair of a cranial flap, yttrium synovectomy and inguinal herniotomy were performed successfully, as was surgical decompression of a flexor pollicis longus bleed. Treatment of a patient with an infected haematoma had limited success, attributed to intermittent suboptimal doses. In 2 patients, satisfactory haemostasis was achieved for multiple dental extractions; subsequent oozing was attributed to suboptimal rFVIIa and/or antifibrinolytic therapy. |
| | |
Authors:
|
J McPherson; L Teague; J Lloyd; D Jupe; J Rowell; P Ockelford; H Ekert; A Street; A Faase; U Hedner |
Related Documents
:
|
1093514 - Hemorrhage due to diffuse erosive gastritis. 10823254 - Use of recombinant factor viia in 3 patients with inherited type i glanzmann's thrombas... 15842354 - Definition of major bleeding in clinical investigations of antihemostatic medicinal pro... 12878564 - Age and left ventricular impairment predict reopening for bleeding. 16084254 - Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis... 3651924 - A second look at the effects of supportive follow-up on smoking cessation. |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Haemostasis Volume: 26 Suppl 1 ISSN: 0301-0147 ISO Abbreviation: Haemostasis Publication Date: 1996 |
Date Detail:
|
Created Date: 1997-02-19 Completed Date: 1997-02-19 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0371574 Medline TA: Haemostasis Country: SWITZERLAND |
Other Details:
|
Languages: eng Pagination: 109-17 Citation Subset: IM |
Affiliation:
|
Haemophilia Treatment Centres, Mater Hospital, Newcastle, Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Australia Child Factor VIIa / therapeutic use* Hemophilia A / drug therapy* Humans Male Middle Aged New Zealand Recombinant Proteins / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Recombinant Proteins; EC 3.4.21.21/Factor VIIa |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dosing and monitoring NovoSeven treatment.
Next Document: Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa.